Novartis will invest $23bn in US-based manufacturing and research and development (R&D) over the next five years, becoming ...

Novartis has announced a massive investment in manufacturing and R&D facilities in the US, including seven new facilities, in ...

Robert F Kennedy Jr's controversial views on vaccines were on display this week during an interview with CBS News in which he ...

Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary ...

In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

The vaccine—aimed at bacterial meningitis and developed by Novartis Vaccines in Siena, Italy—is the first produced using 'reverse vaccinology', in which genomic information rather than the ...

In its March 31 federal complaint, AbbVie, of North Chicago sued Novartis Vaccines & Diagnostics and Grifols Worldwide Operations, of Spain and Ireland, claiming Novartis’ so-called “inventions” are ...

TOKYO (Reuters) -Swiss pharmaceutical giant Novartis will watch "very carefully" how the reciprocal tariff policy proposed by the United States unfolds in early April, Chief Executive Vas Narasimhan ...

(Bloomberg) -- Moves by the incoming Trump Administration may be a boon to drugmakers, Novartis AG Chief Executive Officer Vas Narasimhan said, while concerns over vaccine policies and public ...

Background: Given the broad age range across which the quadrivalent meningococcal conjugate vaccine MenACWY-CRM is used, coadministration with routine vaccines should be evaluated across age ...